Please use this identifier to cite or link to this item:
Title: Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons
Austin Authors: Goh, Su Kah ;Gold, Grace ;Christophi, Christopher ;Muralidharan, Vijayaragavan 
Affiliation: Hepato-Pancreato-Biliary and Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia
Issue Date: 13-Aug-2017
Date: 2017-08-13
Publication information: ANZ Journal of Surgery 2017; 87(12): 987-992
Abstract: The optimal management of oncological conditions is reflected by the careful interpretation of investigations for screening, diagnosis, staging, prognostication and surveillance. Serum tumour markers are examples of commonly requested tests in conjunction with other imaging and endoscopic tests that are used to help clinicians to stratify therapeutic decisions. Serum carbohydrate antigen 19-9 (CA19-9) is a key biomarker for pancreatic cancers. Although this biomarker is considered clinically useful and informative, clinicians are often challenged by the accurate interpretation of elevated serum CA19-9 levels. Recognizing the pitfalls of normal and abnormal serum CA19-9 concentrations will facilitate its appropriate use. In this review, we appraised the biomarker, serum CA19-9, and highlighted the clinical utility and limitations of serum CA19-9 in the investigation and management of pancreatic cancers.
DOI: 10.1111/ans.14131
ORCID: 0000-0002-6684-2521
Journal: ANZ Journal of Surgery
PubMed URL:
Type: Journal Article
Subjects: CA19-9
Clinical utility
Pancreatic cancer
Prognostic value
Serum biomarker
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.